Summary
Zoetis Inc. reported solid financial results for the fiscal year ended December 31, 2025, with total revenue reaching $9.47 billion, a 2% increase year-over-year, driven by a 3% operational revenue growth. This growth was primarily attributed to price increases and contributions from key product franchises, partially offset by the impact of a divestiture. Net income grew 8% to $2.67 billion. The company continues to demonstrate strength in both its U.S. and International segments, with companion animal products representing a significant 70% of total revenue. Key product lines like Simparica/Simparica Trio and Apoquel/Apoquel Chewable remain strong contributors, accounting for a substantial portion of overall revenue. Zoetis also continues to invest in research and development, with expenses totaling $698 million, focusing on both new product development and lifecycle innovation. The company's balance sheet remains robust, with total assets growing to $15.47 billion. Zoetis actively manages its capital structure, including a significant share repurchase program of up to $6 billion, demonstrating a commitment to returning value to shareholders. The company's financial health is supported by a strong credit facility and diverse revenue streams across multiple species and product categories. Looking ahead, Zoetis is focused on its strategic pillars of innovation, customer experience, digital solutions, talent development, sustainability, and operational excellence to drive continued growth in the dynamic animal health market.
Financial Highlights
53 data points| Revenue | $9.47B |
| Cost of Revenue | $2.67B |
| Gross Profit | $6.80B |
| SG&A Expenses | $2.38B |
| Interest Expense | $222.00M |
| Net Income | $2.67B |
| EPS (Basic) | $6.03 |
| EPS (Diluted) | $6.02 |
| Shares Outstanding (Basic) | 443.44M |
| Shares Outstanding (Diluted) | 443.83M |
Key Highlights
- 1Total revenue increased by 2% to $9.47 billion for the fiscal year ended December 31, 2025, driven by operational revenue growth of 3% due to price increases and contributions from key franchises.
- 2Net income attributable to Zoetis grew 8% to $2.67 billion, indicating strong profitability.
- 3Companion animal products continue to be the dominant revenue driver, representing 70% of total revenue, while livestock products accounted for 29%.
- 4Key products Simparica/Simparica Trio and Apoquel/Apoquel Chewable, along with Librela and Solensia, remain significant contributors to revenue.
- 5Research and development expenses increased by 2% to $698 million, underscoring the company's commitment to innovation.
- 6Zoetis continued its share repurchase program, with $2.4 billion remaining under its $6 billion authorization as of December 31, 2025.
- 7The company maintained a strong liquidity position, with cash and cash equivalents totaling $2.31 billion and a solid working capital of $4.53 billion.